Published in J Urol on October 01, 1999
Transrectal quantitative shear wave elastography in the detection and characterisation of prostate cancer. Surg Endosc (2013) 0.98
Imaging prostate cancer. J Urol (1999) 0.78
Three dimensional ultrasound and prostate cancer. World J Urol (2004) 0.77
One drug for epilepsy. Br Med J (1978) 4.87
One drug (phenytoin) in the treatment of epilepsy. Lancet (1976) 4.32
Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet (2005) 3.38
Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer (2012) 2.74
Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry (2001) 2.40
Screening for prostate cancer in the UK. Seems to be creeping in by the back door. BMJ (2001) 2.22
Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry (1976) 2.18
Primary hyperparathyroidism: an analysis of failure of parathyroidectomy. World J Surg (2014) 2.09
Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Hum Mol Genet (1997) 2.02
Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology (2007) 1.94
Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate (1996) 1.85
Large pragmatic randomised studies of new antiepileptic drugs are needed. BMJ (1997) 1.83
Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology (2005) 1.82
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 1.79
Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem (2001) 1.79
Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry (1977) 1.79
Cortical reflex myoclonus. Neurology (1979) 1.68
An epilepsy needs document. Seizure (1993) 1.64
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
A general practice records audit of the process of care for people with epilepsy. Br J Gen Pract (1996) 1.53
Computers in cardiovascular investigation. Br Heart J (1967) 1.53
Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom. BMJ (1999) 1.48
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Placebo-controlled studies in neurology: where do they stop? Neurology (1999) 1.40
Behavior of urothelial carcinoma with respect to anatomical location. J Urol (2007) 1.39
Managing the teenager with epilepsy: paediatric to adult care. Seizure (1997) 1.37
EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate (2007) 1.34
An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer (2012) 1.33
Measurement of the QT interval. Eur Heart J (1985) 1.25
Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry (1995) 1.24
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol (1999) 1.22
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer (2013) 1.22
Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry (1984) 1.22
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene (1999) 1.21
Lhermitte's "sign" due to thoracic cord compression. J Neurol Neurosurg Psychiatry (1986) 1.16
Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene (2006) 1.14
Measuring the impact of epilepsy: the development of a novel scale. Epilepsy Res (1993) 1.14
The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate (2005) 1.13
Caveolin-1 expression is associated with high-grade bladder cancer. Urology (2001) 1.13
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer (2010) 1.12
Risk of accidents in drivers with epilepsy. J Neurol Neurosurg Psychiatry (1996) 1.10
Altered 5-HT metabolism with clonazepam, diazepam and diphenylhydantoin. J Pharm Pharmacol (1975) 1.10
A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology (2002) 1.10
Megaloblastic anemia of infancy secondary to maternal pernicious anemia. N Engl J Med (1966) 1.09
The effectiveness of prophylactic anticonvulsants following neurosurgery. Acta Neurochir (Wien) (1983) 1.09
Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia (1998) 1.08
Phenytoin monotherapy for epilepsy: a long-term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia (1981) 1.08
Manipulation of brain serotonin in the treatment of myoclonus. Lancet (1975) 1.07
Screening for carcinoma of the prostate. BMJ (1990) 1.07
BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J Pathol (2008) 1.07
Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol (2001) 1.05
Ballistic movement overflow myoclonus a form of essential myoclonus. Brain (1977) 1.04
Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry (1987) 1.04
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer (1996) 1.03
Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess (2012) 1.03
Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology (2004) 1.03
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol (1997) 1.02
TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology (2001) 1.02
Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer (1992) 1.02
Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder. Adv Neurol (1986) 1.02
FGF8 isoform b expression in human prostate cancer. Br J Cancer (2003) 1.01
Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res (1997) 1.01
Epilepsy after first seizures: risks and implications. J Neurol Neurosurg Psychiatry (1991) 1.00
Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer (2003) 1.00
A comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry (1986) 0.99
Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene (2006) 0.99
Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer (1998) 0.99
aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol (1999) 0.98
Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab (2004) 0.98
The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception (1986) 0.98
S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer (2004) 0.97
Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. BJU Int (2003) 0.97
Epilepsy in women of childbearing age. BMJ (1989) 0.97
The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate (2008) 0.95
Sudden death and epilepsy. Lancet (1990) 0.95
Modelling the electrical properties of bladder tissue--quantifying impedance changes due to inflammation and oedema. Physiol Meas (2005) 0.95
Genetic instability and transitional cell carcinoma of the bladder. BJU Int (2004) 0.95
Rare trisomy mosaicism diagnosed in amniocytes, involving an autosome other than chromosomes 13, 18, 20, and 21: karyotype/phenotype correlations. Prenat Diagn (1997) 0.94
State-of-the-art staging in prostate cancer. BJU Int (2001) 0.93
Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. J Eval Clin Pract (2000) 0.93
UK emissions of the greenhouse gas nitrous oxide. Philos Trans R Soc Lond B Biol Sci (2012) 0.92
Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol (1991) 0.92
Uraemic myoclonus: an example of reticular reflex myoclonus? J Neurol Neurosurg Psychiatry (1979) 0.92
Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol (2006) 0.92
Label-free quantitative proteomics reveals differentially regulated proteins influencing urolithiasis. Mol Cell Proteomics (2011) 0.90
Automatic detection of hippocampal atrophy on magnetic resonance images. Magn Reson Imaging (1999) 0.90
Electrical impedance spectroscopy and the diagnosis of bladder pathology: a pilot study. J Urol (2002) 0.90
Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer (1998) 0.90
Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate (2000) 0.90
Comparing antiepileptic drugs. Curr Opin Neurol (1996) 0.89
Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate (1998) 0.89
The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures. J Neurol Neurosurg Psychiatry (1985) 0.89